Product Images Memantine Hydrochloride

The text describes a figure showing the time course of change from baseline in ADCS-ADL score for patients who completed 28 weeks of treatment. There is information in the figure about the mean change from baseline and standard error of the mean.*

The text seems to be a figure caption describing a graph. It shows the cumulative percentage of patients completing 28 weeks of double-blind treatment with specified changes from baseline in ADCS-ADL scores. It does not provide any further information.*

The figure 4 shows the cumulative percentage of patients who completed 28 weeks of double-blind treatment with specified changes from baseline in SIB scores. No further information is available to generate a more specific description.*

The figure shows the time course of the change from baseline in ADCS-ADL score for patients who completed 24 weeks of treatment. The text also includes some headings and labels related to the chart, such as "Moan (+ SEM) Change from Baseline" and "Weeks of Treatment," but there is not enough context to provide a full description of the study or its results.*

This is a graph (Figure 7) that shows the time course of the change from baseline in SIB score (a measure of cognitive function) for patients who completed 24 weeks of treatment. There is not much context or additional information but it seems to be related to a clinical trial.*

This text describes a figure labeled as "Figure 8" which shows the cumulative percentage of patients who completed 24 weeks of double-blind treatment and the specified changes from the baseline in SIB scores. It is not possible to provide specific details about the changes or treatment as the text only provides a brief context.*

Memantine HCI is a medication available in a pack of 60 tablets with each tablet containing a significant amount of Memantine Hydrochloride. Actavis is the brand that has manufactured this medication, and it is only available on prescription. It is recommended that patients follow the directions provided on the package insert for the proper dosage. It is very important to keep the medication away from children and store at room temperature (between 20-25°C). Moz Phama CrH & KGaA is the licensing company while Actavis maintains a facility for manufacturing and distribution in the USA.*

This is a description of Memantine Hydrochloride tablets, with NDC number 0591-3875-60, manufactured by Actavis. Each tablet contains memantine, with usual dosage indicated on the packaging and prescribing information. The drug should be kept out of reach of children and stored at controlled room temperature. The tablets are licensed from Merz Pharma Gmbé & o.KGak and distributed by Retaus Parm, Inc. in Parsippany, USA.*

The provided text is not readable.*